Pfizer acquires Redvax GmbH
5 January 2015 | By Pfizer
Acquisition provides Pfizer with a preclinical CMV vaccine candidate...
List view / Grid view
News
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
Midatech Pharma awarded EU grant funding to support training and research into glycan based multivalent immunotherapeutics
17 December 2014 | By Midatech Pharma
Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant...
Curie-Cancer and GamaMabs Pharma renew their research partnership to develop an antibody for gynecological cancers
16 December 2014 | By Curie-Cancer
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer...
Kymab and the Wellcome Trust initiate Ebola Project
16 December 2014 | By Kymab
Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...
New targeted drugs could treat drug-resistant skin cancer
15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...
Molecular methods rapidly gain ground in infectious disease diagnostics
12 December 2014 | By Frost & Sullivan
Convergence of immunodiagnostic and molecular tests will help meet demand in developed countries, says Frost & Sullivan...
Anticoagulant effect of Eliquis (apixaban) reversed by two separate 4-factor prothrombin complex concentrates in healthy subjects
10 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects...
ZoBio and Domainex join forces to deliver crucial drug target information to support FORMA therapeutics’ drug discovery programs
10 December 2014 | By ZoBio and Domainex
ZoBio (Leiden, The Netherlands) and Domainex Ltd. (Cambridge, UK) announce a collaboration with FORMA Therapeutics (Watertown, MA, USA) to provide NMR-based structural biology services for a substantial panel of FORMA drug targets...
Alizé Pharma announces positive results for AZP-531, its unacylated ghrelin analog, from two Phase I clinical trials in healthy volunteers and obese subjects
10 December 2014 | By Alizé Pharma SAS
Based on these results, a Phase Ib trial has been launched in type 2 diabetes patients...
Codexis uses its CodeEvolver® protein engineering platform technology to develop an enzyme therapeutic candidate for the potential treatment of phenylketonuria (PKU) via oral administration
8 December 2014 | By Codexis
Codexis, Inc. announced that it has developed a novel enzyme therapeutic product candidate for the potential treatment of phenylketonuria (PKU) via oral administration...
SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors designed for the topical treatment of retinal disease
8 December 2014 | By SciFluor Life Sciences
SciFluor Life Sciences, LLC announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,901,144 with claims covering the novel compound SF0166...
reViral receives over US$1Mn in funding
4 December 2014 | By reViral
Second tranche of Seeding Drug Discovery award from Wellcome Trust Innovations...
Alizé Pharma acquires exclusive worldwide rights on a new peptide to tackle bone diseases
3 December 2014 | By Alizé Pharma III SAS
Dr. David Clemmons, co-inventor of the technology and a highly reputable key opinion leader in endocrinology and metabolism, will collaborate on the drug optimization and development programs...
Evotec and Sanofi discuss major multi-component strategic collaboration
3 December 2014 | By Evotec
Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.
